[Form 4] TEVA PHARMACEUTICAL INDUSTRIES LTD Insider Trading Activity

Rhea-AI Filing Summary

Teva Pharmaceutical Industries (TEVA) executive Christine Fox reported equity compensation activity and a related share sale. On 11/20/2025, 63,492 restricted share units vested and were settled into the same number of ordinary shares. On the same date, she sold 28,229 ordinary shares at $24.7803 per share, with the filing stating this represented shares required to be sold to cover tax withholding obligations tied to the vesting.

The sale was carried out under a Rule 10b5-1 trading plan adopted on August 11, 2025. After these transactions, Fox directly beneficially owned 63,647 ordinary shares and held 126,984 restricted share units that may settle into additional ordinary shares or their cash value under the company’s compensation arrangements.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fox Christine

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV L3 6944020

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Head of U.S. Commercial

3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	11/20/2025		M		63,492	A	(2)	91,876	D
Ordinary Shares(1)	11/20/2025		S(3)		28,229(4)	D	$24.7803	63,647	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(2)	11/20/2025		M			63,492	(5)	(5)	Ordinary Shares(1)	63,492	$0	126,984	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

3. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025.

4. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

5. Restricted share units were granted on November 20, 2023, with 63,492 vested on each of November 20, 2024 and November 20, 2025, and 63,492 vesting on each of November 20, 2026 and November 20, 2027.

	/s/ Dov Bergwerk as attorney-in-fact for Christine Fox	11/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did TEVA executive Christine Fox report on this Form 4?

Christine Fox reported the vesting and settlement of 63,492 restricted share units into ordinary shares of Teva Pharmaceutical Industries Ltd. (TEVA) on 11/20/2025, along with a related sale of shares.

How many TEVA shares did Christine Fox sell and at what price?

On 11/20/2025, Christine Fox sold 28,229 ordinary shares of TEVA at a price of $24.7803 per share.

Why were 28,229 TEVA shares sold by Christine Fox?

The filing states that the 28,229 shares sold represented the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units.

Was the TEVA share sale by Christine Fox under a Rule 10b5-1 trading plan?

Yes. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Christine Fox on August 11, 2025, as disclosed in the filing.

How many TEVA shares does Christine Fox own after the reported transactions?

Following the reported transactions, Christine Fox directly beneficially owned 63,647 ordinary shares of Teva Pharmaceutical Industries Ltd.

How many restricted share units does Christine Fox hold after these TEVA transactions?

After the vesting on 11/20/2025, Christine Fox beneficially owned 126,984 restricted share units, each representing a contingent right to receive one ordinary share or its cash value.

What is the vesting schedule for Christine Fox’s TEVA restricted share units?

The restricted share units were granted on November 20, 2023, with 63,492 units vesting on each of November 20, 2024 and November 20, 2025, and an additional 63,492 units scheduled to vest on each of November 20, 2026 and November 20, 2027.